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trial: “Intensive Versus Moderate Lipid Lowering With Statins
After Acute Coronary Syndromes” (2). On the active debate
regarding whether the appropriate treatment should be based on
the dose of the statin or the achieved LDL, we agree that there
have not been trials that directly compare 2 strategies of titrating to
a specific LDL-C goal. All the trials use different, largely fixed
regimens of a specific statin dose (either with intensive vs.
moderate, or of statin therapy vs. placebo). In PROVE IT–TIMI-
22, we designed the trial very specifically to have 2 different levels
of achieved LDL-C so as to be able to compare patients who
reached an average of 100 mg/dl, as recommended in the
National Cholesterol Education Program (NCEP) III guidelines,
versus a much lower LDL-C with a more intensive regimen, with
the final median LDL-C values of 95 and 62 mg/dl, respectively.
Almost a decade ago, the NCEP Guideline committee adopted
a practical approach to lipid lowering—where members specified
target levels for LDL-C and other lipid levels. This was believed to
be a means of having physicians identify high cholesterol values in
patients and adjust treatment accordingly. The evidence directly
supporting this approach does not exist, as recently lamented (3),
but can be inferred from all the randomized trials.
For clinical care, we take a practical view. If we have a patient
with an LDL70 mg/dl on a moderate dose of a statin, we do not
feel compelled to increase the dose. However, we are currently
conducting the IMPROVE IT trial to address this question, to
ascertain whether an even lower LDL is even better. It compares
strategies using simvastatin versus simvastatin plus ezetimibe,
which are anticipated to have achieved LDL levels of 65 versus
50 mg/dl, respectively. When the trial is completed in several
years, we may have evidence to support an even lower target
level for LDL.
For additional targets of therapy, we agree, and published the
prospective analysis relating clinical event rates to levels of achieved
C-reactive protein (4). We similarly have recently found triglyc-
erides to be an important target for therapy (5). We agree that
HDL is an important target as well, and we anticipate new
approaches to address this important risk factor. All these data
support the call for comprehensive management of all components
of dyslipidemia.
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Depression and Heart Failure:
Why the Link Continues
to Elude Us
Rutledge et al.’s (1) important and comprehensive review of depres-
sion in heart failure highlights the relative neglect in investigating
the key parameters of this important association in the litera-
ture. The researchers remind us there remains as yet no in-
vestigation of the effects of a depression intervention on objective
clinical outcomes such as survival or secondary cardiac events in a
heart failure (HF) population.
However, although their useful review emphasized the biolog-
ical connections between HF and depression, some of the emerg-
ing key issues on the link between depression and heart disease
possibly emphasize more the social and perceptual impacts of
effect.
For example, we know that depression has a negative impact on
social networks, and it could be that it partially mediates its effects
on cardiovascular systems via this variable. It is now a well-
established finding that those individuals who are more socially
integrated—for example, in long-term relationships or connected
to communities or organizations—display lower risks of premature
all-cause mortality than do those who are not so well integrated
socially (2).
Piferi and Lawler (2) have recently demonstrated that social
support not only had a positive impact on blood pressure but giving
social support appears to represent a separate construct from
receiving social support and may exert a uniquely positive effect on
health. It might be that future studies on depression and HF,
particularly intervention ones, would need to take this kind of
social mediating variable into account, and be highly specific as to
whether giving or receiving social support was measured.
Another key aspect of depression, which should be part of the
future of research into depression and HF, is the specific impact of
low mood on perception. For example, Ruo et al. (3) recently
established that depression has a clinically significant effect on
self-rated health among women with coronary disease, even after
adjustment for clinical diagnoses. The magnitude of this impact of
depression on self-rated health was similar to that of major
cardiovascular events such as angina, myocardial infarction, angio-
plasty, HF, or coronary bypass surgery.
Whether depressed individuals are less compliant with treat-
ments and medical advice, and whether they are unlikely to attend
follow-up, are recalcitrant over exercise, losing weight, improving
diet, and quitting smoking remain open questions. Thus, the
precise pathway via how their depression impacts on their physical
health continues to be a mystery.
This gap in our current knowledge probably accounts for the
recent failure to demonstrate a significant impact on physical out-
comes for treating depression following myocardial infarction (4).
1503JACC Vol. 49, No. 13, 2007 Correspondence
April 3, 2007:1502–4
Future research efforts into HF and depression, as well as heart
disease and psychological states in general, need to measure more
precisely the multiplicity of impacts of depression on an individual
in order to ultimately produce effective treatments. Currently, the
field seems intent on importing the way we treat standard
depression in psychiatry into the way depression should be ap-
proached in cardiology. It is highly unlikely this is going to help
heart patients in the long run, as this would probably neglect the
unique and various specific impacts of depression in heart disease
and vice versa.
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Reply
Dr. Persaud offers several valuable comments concerning our
recent review (1). The relationship between depression and heart
failure (HF) is complex, and we fully agree that furthering our
understanding of how these conditions interrelate will require the
study of important psychosocial factors such as social support and
social isolation in addition to biological mechanisms.
Although our review primarily focused on rates and prospective
significance of depression in HF patients, we would like to use
Dr. Persaud’s comments as a platform to make several specific
suggestions concerning applications to treatment.
First, treating and understanding depression’s effects on HF
patients begins at the stage of symptom recognition, a surprisingly
difficult task. Depression is notoriously underrecognized in medical
patients. The clinical presentations of HF and depression are often
similar, complicating diagnosis and assessment of treatment ben-
efits. Social stigmas against mental health diagnoses can make
patients reluctant to acknowledge depressive symptoms. Depres-
sion may delay treatment-seeking behaviors in some, while in-
creasing health care utilization in others. Depression symptoms
can also vary widely across patients, and the meaning of these
differences for HF is not known. Collectively, these factors
undermine and may even argue against the application of stan-
dardized depression treatments in HF populations.
Second, efficacious treatments for depression are still lacking,
despite the development of state-of-the-art pharmacotherapies. A
substantial patient population does not respond and/or maintains
clinically significant symptoms despite treatment attempts (2), and
responsiveness may itself have prognostic importance (3).
Third, the presence of depression is not random; rather, it is
disproportionately diagnosed among patients who are female,
those suffering more advanced disease, those who are socially
isolated, and those of lower socioeconomic status. These factors
can affect patients’ presenting symptoms, their ability or willing-
ness to participate in treatment, their responsiveness to treatment,
and their susceptibility to relapse.
Our review found the treatment literature for depression in HF
to be poorly developed and methodologically inconsistent. At this
early stage of research—and lacking any conclusive treatment
evidence for survival or event outcomes from the much larger
coronary artery disease literature—we believe it would be impru-
dent to call for clinical trials in HF at this time. Instead, we hope
that our findings and insights from colleagues such as Dr. Persaud
can be used to advance the treatment research in this area for
potential future applications.
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